Tuberculosis: WHO-endorsed test offers rapid detection

by Editor

March 3, 2013 | 9:40 am
  |     |     |   Start Conversation

A diagnostic test for tuberculosis (TB), endorsed by the World Health Organisation (WHO), can accurately and quickly detect both TB and drug-resistant strains, according to a new study released by the Cochrane Centre, Calabar.

According to Olabisi Oduwole, research officer at the centre, the authors of a new systematic review assessing the diagnostic accuracy of the Xpert® MTB/RIF test published in The Cochrane Library, their study can provide timely advice for clinicians and policy makers in countries where TB is a major public health problem.

Health researches reveal that millions of people develop TB every year. Around 13 percent of cases occur in people living with HIV, and more than a quarter of these people die as a result.

The researchers, from the Cochrane Infectious Diseases Group, McGill University and the Foundation for Innovative New Diagnostics (FIND), analysed data from 18 studies involving a total of 7,816 people, with most studies being carried out in low- and middle-income countries.

Meanwhile, drug resistance is a major public health problem that further complicates efforts to control TB. Multidrug-resistant TB is defined as, resistance to rifampicin and isoniazid, which are two of the most effective and widely used anti-TB drugs.

Xpert® (Cepheid Inc, California) is a diagnostic test endorsed by the WHO, which simultaneously detects TB and resistance to rifampicin, as an indicator of multidrug resistance.

The test takes around two hours, with minimal hands-on technical time required. Like sputum smear microscopy, which relies on detecting TB with a microscope in a laboratory, Xpert requires a sample of sputum.

However, while thousands of bacteria must be present in each millilitre of sample for TB to be detected under the microscope, Xpert can detect TB bacteria at much lower concentrations. In addition, the conventional microscopy approach does not detect drug resistance. Instead, TB has to be grown in the lab. This presents problems, especially for multidrug-resistant TB, due both to the length of time required for the cultures to grow and the specialised laboratories and highly skilled staff needed.

The results show that when Xpert is used to screen 1,000 people, 150 of whom have TB, it picks up 132 of the 150 cases (88%) and falsely diagnoses 17 (2%) with TB. This is in a scenario where it is being used as a replacement for smear microscopy. In a scenario where Xpert is being used as a replacement for culture-based drug susceptibility testing, it is also able to detect the equivalent of 141 out of 150 cases (94%) of rifampicin resistance.


by Editor

March 3, 2013 | 9:40 am
12893  |   93   |   0  |   Start Conversation

Big Read |  

Does Conoil need a makeover?

Does Conoil need a makeover?

One of Nigeria’s oldest company, Conoil Plc is looking like a company in need of a game changer as its...

MTN Felele

Banking App